Fosamprenavir

CHEMBL1664 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

585.6 g/mol

LogP

1.8

Phase

4

This prodrug is converted in the body to amprenavir, an HIV protease inhibitor that blocks an enzyme the virus needs to make functional copies of itself. It is used as part of combination antiretroviral therapy to treat HIV infection.

Berat Molekul

585,6000 g/mol

LogP

1,80

TPSA

186,00 Å²

Lipinski RO5

Gagal

Area Terapeutik

Cardiovascular Disease Gastroesophageal Reflux Disease HIV/AIDS Hepatitis C

Mekanisme Kerja

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1

InChI

InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1

Molecular Formula

C25H36N3O9PS

HBD / HBA

4 / 11

Ikatan yang Dapat Dirotasi

14

Atom Berat

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This prodrug is converted in the body to amprenavir, an HIV protease inhibitor that blocks an enzyme the virus needs to make functional copies of itself. It is used as part of combination antiretroviral therapy to treat HIV infection.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Fosamprenavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1664. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 131536. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Fosamprenavir di PillFYI

Struktur

Data Cepat

Rumus: C25H36N3O9PS
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Fosamprenavir

Area Terapeutik

Mekanisme Kerja

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Pertanyaan yang Sering Diajukan

References & Data Sources

Embed This Widget